Xilio Therapeutics, Inc. (XLO): Nasdaq/NYSE listing notice — Xilio Therapeutics receives second Nasdaq deficiency letter for low stockholders' equity; bid price also non-compliant

Xilio Therapeutics, Inc.

Reported stockholders' equity of $7.069M as of June 30, 2025, below $10M minimum required for Nasdaq Global Select Market.
Company has 45 days (until Oct 6, 2025) to submit a compliance plan; Nasdaq may grant up to 180-day extension.
Also remains out of compliance with $1.00 minimum bid price requirement, initial cure period expires Oct 1, 2025.
No immediate effect on listing; company may also seek transfer to Nasdaq Capital Market.

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.95

Xilio Therapeutics, Inc. received a nasdaq deficiency notice notice regarding stockholders equity (rules 5450(b)(1)(A)).

Exchange: nasdaq
Notice: deficiency notice
Deficiency: stockholders equity
Rules: 5450(b)(1)(A)

Exact text from the filing

August 22, 2025, Xilio Therapeutics, Inc. (the “Company”) received a deficiency letter (the “Letter”) from the Listing Qualifications Department (the “Staff”) of the Nasdaq Stock Market, LLC (“Nasdaq”) notifying the Company that it is not in compliance with the requirement to maintain a minimum of $10.0 million in stockholders’ equity, as required by Nasdaq Listing Rule 5450(b)(1)(A) for continued listing on The Nasdaq Global Select Market. As stated in the Letter, the Company reported stockholders’ equity of $7,069,000 in its Quarterly Report on Form 10-Q for the quarter ended June 30, 2025.

View on SEC.gov

19 listing & compliance notices filed in the last 30 days. Browse all listing & compliance notices →

Xilio Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001558370-25-011802

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.